Effectiveness of azithromycin in aspiration pneumonia: A prospective observational study

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Marumo, Satoshi ^a,b   Teranishi, Takashi ^b   Higami, Yuichi ^b   Koshimo, Yoshihiko ^b   Kiyokawa, Hirofumi ^b   Kato, Motokazu ^b  

^a Kitano Hospital   (Japan)

^b Kishiwada City Hospital   (Japan)

Author keywords

Aspiration pneumonia; Azithromycin; Nursing and healthcare associated pneumonia

Indexed keywords

AZITHROMYCIN; SULTAMICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; SULBACTAM;

AGED; ANTIBIOTIC THERAPY; ARTICLE; ASPIRATION PNEUMONIA; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DRUG COST; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FEVER; GLOMERULUS FILTRATION RATE; HEALTH CARE ASSOCIATED PNEUMONIA; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; NURSING ASSOCIATED PNEUMONIA; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; ADULT; COMPARATIVE STUDY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PNEUMONIA, ASPIRATION; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMPICILLIN; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PNEUMONIA, ASPIRATION; PROSPECTIVE STUDIES; SULBACTAM; TREATMENT OUTCOME;

EID: 84923854015     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-014-0685-y     Document Type: Article

References (25)

1. Fernandez-Sabe N, Carratala J, Roson B, Dorca J, Verdaguer R, Manresa F, Gudiol F: Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine 2003, 82(3):159-169.
2. Kohno S, Imamura Y, Shindo Y, Seki M, Ishida T, Teramoto S, Kadota J, Tomono K, Watanabe A: Clinical practice guidelines for nursing- and healthcare-associated pneumonia (NHCAP) [complete translation]. Respir Investig 2013, 51(2):103-126.
3. Teramoto S, Fukuchi Y, Sasaki H, Sato K, Sekizawa K, Matsuse T: High incidence of aspiration pneumonia in community- and hospital-acquired pneumonia in hospitalized patients: a multicenter, prospective study in Japan. J Am Geriatr Soc 2008, 56(3):577-579.
4. Bartlett JG, Gorbach SL, Finegold SM: The bacteriology of aspiration pneumonia. Am J Med 1974, 56(2):202-207.
5. Lode H: Microbiological and clinical aspects of aspiration pneumonia. J Antimicrob Chemother 1988, 21(Suppl C):83-90.
6. El-Solh AA, Pietrantoni C, Bhat A, Aquilina AT, Okada M, Grover V, Gifford N: Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Rrespir Crit Care Med 2003, 167(12):1650-1654.
7. American Thoracic Society; Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Rrespir Crit Care Med 2005, 171(4):388-416.
8. Pfaller MA, Farrell DJ, Sader HS, Jones RN: AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis 2012, 55(Suppl 3):S187-S193.
9. Sefton AM, Maskell JP, Beighton D, Whiley A, Shain H, Foyle D, Smith SR, Smales FC, Williams JD: Azithromycin in the treatment of periodontal disease. Effect on microbial flora. J Clin Periodontol 1996, 23(11):998-1003.
10. Barlow G, Nathwani D, Davey P: The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax 2007, 62(3):253-259.
11. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58(5):377-382.
12. Miyashita N, Matsushima T, Oka M, Japanese Respiratory S: The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med 2006, 45(7):419-428.
13. Weinstein MP, Klugman KP, Jones RN: Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 2009, 48(11):1596-1600.
14. Craig WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26(1):1-10. quiz 11-12.
15. Tice AD, Rehm SJ, Dalovisio JR, Bradley JS, Martinelli LP, Graham DR, Gainer RB, Kunkel MJ, Yancey RW, Williams DN: Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 2004, 38(12):1651-1672.
16. Berry V, Thorburn CE, Knott SJ, Woodnutt G: Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob Agents Chemother 1998, 42(12):3193-3199.
17. Pankey GA, Sabath LD: Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 2004, 38(6):864-870.
18. Bakker-Woudenberg IA, van Vianen W, van Soolingen D, Verbrugh HA, van Agtmael MA: Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination. Antimicrob Agents Chemother 2005, 49(6):2387-2398.
19. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A: Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009, 33(1):153-159.
20. Watanabe A, Yanagihara K, Matsumoto T, Kohno S, Aoki N, Oguri T, Sato J, Muratani T, Yagisawa M, Ogasawara K, Koashi N, Kozuki T, Komoto A, Takahashi Y, Tsuji T, Terada M, Nakanishi K, Hattori R, Hirako Y, Maruo A, Minamitani S, Morita K, Wakamura T, Sunakawa K, Hanaki H, Ohsaki Y, Honda Y, Sasaoka S, Takeda H, Ikeda H, et al: Nationwide surveillance of bacterial respiratory pathogens conducted by the Survellance Committee of Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Clinical Microbiology in 2009: general view of the pathogens' antibacterial susceptibility. J Infect Chemother 2012, 18(5):609-620.
21. Kohno S, Tateda K, Kadota JI, Fujita J, Niki Y, Watanabe A, Nagashima M: Contradiction between in vitro and clinical outcome: Intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia. J Infect Chemother 2013, 20(3):199.
22. Chiu LM, Menhinick AM, Johnson PW, Amsden GW: Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers. J Antimicrob Chemother 2002, 50(6):1075-1079.
23. Rodvold KA, Danziger LH, Gotfried MH: Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 2003, 47(8):2450-2457.
24. Fukuda Y, Yanagihara K, Higashiyama Y, Miyazaki Y, Hirakata Y, Mukae H, Tomono K, Mizuta Y, Tsukamoto K, Kohno S: Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae. Eur Respir J 2006, 27(5):1020-1025.
25. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K: Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012, 68(5):479-503.